Table 3. Association of H2-receptor antagonists (H2RAs) use with prevalent NAFLD according to selected risk factors; NHANES, 2001 – 2006.
| Crude OR (95% CI) | Adjusted¥ OR (95% CI) | |
|---|---|---|
| Sex | ||
| Male | 0.88 (0.55 – 1.42) | 0.18 (0.04 – 0.79) |
| Female | 1.04 (0.57 – 1.92) | 0.78 (0.26 – 2.35) |
| Age | ||
| ≤ 60 yrs. | 1.03 (0.62 – 1.69) | 0.39 (0.11 – 1.38) |
| > 60 yrs. | 1.25 (0.72 – 2.17) | 0.46 (0.13 – 1.57) |
| BMI | ||
| < 25 | 2.20 (0.94 – 5.12) | 2.15 (0.53 – 8.75) |
| 25-30 | 0.93 (0.51 – 1.69) | 0.31 (0.07 – 1.37) |
| ≥ 30 | 0.66 (0.37 – 1.15) | 0.13 (0.02 – 1.05) |
| IR | ||
| No | 0.80 (0.34 – 1.88) | 0.72 (0.25 – 2.11) |
| Yes | 0.33 (0.13 – 0.86) | 0.22 (0.05 – 0.95) |
OR, odds ratio; CI, confidence interval; IR, insulin resistance
¥
Unconditional logistic regression model, adjusted for PPIs and H1RAs use, age, sex, ethnicity, socioeconomic status, waist circumference, physical activity, smoking status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia